In re Eastman Kodak Company Securities Litigation

District Court, W.D. New York·Decided August 2, 2021·No. 6:21-cv-06418·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK

In re EASTMAN KODAK COMPANY DECISION AND ORDER SECURITIES LITIGATION. 6:21-CV-6418 EAW

INTRODUCTION This lawsuit consists of two consolidated matters, one of which was filed in the United States District Court for the District of New Jersey on August 13, 2020 (Tang v. Eastman Kodak Co., 6:21-cv-6418), and the other in the Southern District of New York on August 26, 2020 (McAdams v. Eastman Kodak Co., 6:21-cv-6449). Both matters were transferred to this District on or about May 28, 2021 and June 15, 2021, respectively. Pursuant to a stipulation of the parties and approved by Order of the Court entered June 22, 2021, the matters were consolidated for all purposes into one action and denominated “In re Eastman Kodak Company Securities Litigation” with the case number from the Tang action assigned; the McAdams case was administratively terminated; and a directive was entered that any subsequently filed actions arising out of the same subject matter of this action be consolidated. (Dkt. 891). When the cases were transferred, both had multiple motions pending for the appointment of lead plaintiff. For the reasons set forth below, the Court grants the motion filed by Les Investissements Kiz Inc. (“Kiz Inc.”) and UAT Trading Service, Inc. (“UAT”)

1 This citation and all subsequent docket citations will be to the filings in Tang v. Eastman Kodak Co., 6:21-cv-6418, now titled “In re Eastman Kodak Company Securities Litigation,” unless otherwise specified. (Dkt. 27) and appoints those entities as lead plaintiff and Kaplan Fox & Kilsheimer LLP and Labaton Sucharow LLP as lead counsel. The remaining pending motions for appointment as lead plaintiff are denied. (Dkt. 18; Dkt. 31).

BACKGROUND I. Factual Background Plaintiffs commenced this federal securities class action against Eastman Kodak Company (“Kodak”) and certain of its former officers and directors. (Dkt. 1 at ¶¶ 1, 2). The complaint alleges that in a July 27, 2020 statement to media outlets, Kodak announced

a “new manufacturing initiative” with the United States International Development Finance Corporation (“DFC”) involving a response to the COVID-19 pandemic. (Id. at ¶¶ 2, 27). On the same day, Kodak’s CEO and Executive Chairman, defendant Jim Continenza (“Continenza”), and other Kodak officers and directors were granted considerable stock options. (Id. at ¶¶ 3, 34). The price of Kodak’s shares jumped 200%

on July 28, 2020, following news that Kodak won a government loan from the DFC to produce pharmaceutical ingredients to combat COVID-19, and the stock price continued to surge the following day. (Id. at ¶¶ 4, 29-30). In the days that followed, media outlets reported that the award of stock options to Continenza was unusual, causing the share prices to drop. (Id. at ¶¶ 5-6, 38). An investigation into potential violations of securities

laws and United States Securities and Exchange Commission (“SEC”) regulations was requested. (Id. at ¶¶ 7-8, 39-40). On August 7, 2020, the DFC announced that the allegations of wrongdoing by Kodak raised serious concerns and that the DFC would not proceed further with its July 28, 2020 Letter of Interest unless the allegations were cleared. (Id. at ¶¶ 13, 47). This news caused Kodak’s share prices to further decline. (Id. at ¶¶ 14, 47). The complaint alleges two causes of action: first, against all defendants for violation

of § 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder (id. at ¶¶ 69-79); and second, against the individual defendants for violation of § 20(a) of the Securities Exchange Act of 1934 (id. at ¶¶ 80-83). The complaint alleges a class period of July 27, 2020 through August 7, 2020, and the claims are asserted on behalf of all persons or entities that purchased or otherwise acquired Kodak common stock during that

period. (Id. at ¶ 1). II. Procedural Background Plaintiffs filed Tang v. Eastman Kodak Co., 6:21-cv-6418, in the United States District Court for the District of New Jersey on August 13, 2020. Then, on August 26, 2020, McAdams v. Eastman Kodak Co., 6:21-cv-6449, was filed in the United States

District Court for the Southern District of New York. Both matters were transferred to this District on May 28, 2021 and June 15, 2021, respectively. By Stipulation and Order entered June 22, 2021, the matters were consolidated for all purposes into one action and McAdams was administratively terminated. (Dkt. 89). Prior to transfer to this District, a number of motions for the appointment of lead

plaintiff were filed in both cases. (See Tang, Dkt. 15 (Broward Motorsports Holdings LLC); Dkt. 18 (Charles Satterwhite, Terry Butler, and Yiki Woodling (collectively “the Satterwhite Group”)); Dkt. 19 (Gary Eberhard); Dkt. 22 (Scott Reynolds, SRR Fortress Capital LLC); Dkt. 25 (Margaretha Welkhammer); Dkt. 26 (Doug Atkin); Dkt. 27 (Kiz Inc. and UAT); Dkt. 31 (John McMullan (“McMullan”)); Dkt. 32 (Daniel Yannes); Dkt. 33 (Alexander Enciso); Dkt. 34 (Fred Khachi, Elaine Khachi, Sasan Payvar, and Domenic Pesce); and Dkt. 35 (Kevin Harte and Alfred Fenelle); McAdams, Dkt. 7 (Broward

Motorsports Holdings LLC); Dkt. 11 (Gary Eberhard); Dkt. 14 (Satterwhite Group); Dkt. 15 (Scott Reynolds and SRR Fortress Capital LLC); Dkt. 19 (Doug Atkin); Dkt. 22 (Margaretha Welkhammer); Dkt. 23 (Alexander Enciso); Dkt. 27 (McMullan); Dkt. 28 (Kiz Inc. and UAT); Dkt. 34 (Fred Khachi, Elaine Khachi, Sasan Payvar, and Domenic Pesce); and Dkt. 37 (Kevin Harte and Alfred Fenelle)). Many of these motions were

thereafter withdrawn,2 leaving only the motions of Kiz Inc. and UAT (Dkt. 27), McMullan (Dkt. 31), and the Satterwhite Group (Dkt. 18) pending before the Court. On October 13, 2020, the Satterwhite Group filed their motion for appointment as lead plaintiff. (Dkt. 18). They filed a supplemental brief on November 2, 2020 (Dkt. 47), and reply brief on November 9, 2020 (Dkt. 50). On October 13, 2020, Kiz Inc. and UAT

filed their motion for appointment as lead plaintiff (Dkt. 27; Dkt. 28; Dkt. 29), supplemental brief on November 2, 2020 (Dkt. 49), and reply brief on November 9, 2020 (Dkt. 52). McMullan also filed his motion for appointment as lead counsel on October 13,

2 In the Tang action, Dkt. 15 was withdrawn by Dkt. 41; Dkt. 19 was withdrawn by Dkt. 42; Dkt. 22 was withdrawn by Dkt. 46; Dkt. 25 was withdrawn by Dkt. 36; Dkt. 26 was withdrawn by Dkt. 40; Dkt. 32 was withdrawn by Dkt. 43; Dkt. 33 was withdrawn by Dkt. 37; Dkt. 34 was withdrawn by Dkt. 44 and Dkt. 45; and Dkt. 35 was withdrawn by Dkt. 38. In McAdams, Dkt. 7 was withdrawn by Dkt. 48; Dkt. 11 was withdrawn by Dkt. 53; Dkt. 15 was withdrawn by Dkt. 58; Dkt. 19 was withdrawn by Dkt. 46; Dkt. 23 was withdrawn by Dkt. 42; Dkt. 34 was withdrawn by Dkt. 59; and Dkt. 37 was withdrawn by Dkt. 43. 2020 (Dkt. 31), supplemental brief on November 2, 2020 (Dkt. 48), and reply brief on November 9, 2020 (Dkt. 51). DISCUSSION

I. Legal Standard The Private Securities Litigation Reform Act (“PLSRA”) provides that a court shall appoint the “most adequate plaintiff” to represent the class; that is, the plaintiff “that the court determines to be most capable of adequately representing the interests of class members.” 15 U.S.C. § 78u-4(a)(3)(B)(i); see also Chitturi v. Kingold Jewelry, Inc., No.

20-CV-2886-LDH-SJB, 2020 WL 8225336, at *3 (E.D.N.Y. Dec. 22, 2020) (“The PSLRA requires the court to appoint as ‘lead plaintiff’ the member of the class that it determines to be the ‘most adequate plaintiff,’ i.e., the member ‘most capable of adequately representing the interests of class members.’” (quoting 15 U.S.C. § 78u-4

Free access — add to your briefcase to read the full text and ask questions with AI

In re Eastman Kodak Company Securities Litigation, (W.D.N.Y. 2021).

In re Eastman Kodak Company Securities Litigation (In re Eastman Kodak Company Securities Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.
589 F. Supp. 2d 388 (S.D. New York, 2008)
In re Gentiva Securities Litigation
281 F.R.D. 108 (E.D. New York, 2012)